Titan Pharmaceuticals, Inc.
$2.34-11.36%($-0.30)
TickerSpark Score
50/100
73
Valuation
40
Profitability
55
Growth
52
Health
30
Momentum
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TTNP research report →
52-Week Range0% of range
Low $2.33
Current $2.34
High $15.15
Companywww.titanpharm.com
Titan Pharmaceuticals, Inc. , a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform.
- CEO
- Weei Jye Chay
- IPO
- 1996
- Employees
- 4
- HQ
- Petaling Jaya, KY
Price Chart
-60.56% · this period
Valuation
- Market Cap
- $3.11M
- P/E
- 20.58
- P/S
- 3.22
- P/B
- 0.00
- EV/EBITDA
- 2653.02
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 32.98%
- Op Margin
- 8.42%
- Net Margin
- 7.82%
- ROE
- 0.00%
- ROIC
- 0.00%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-4,706,000 · 15.50%
- EPS
- $-5.23 · 29.42%
- Op Income
- $-4,557,000
- FCF YoY
- 45.31%
Performance & Tape
- 52W High
- $15.15
- 52W Low
- $2.33
- 50D MA
- $4.38
- 200D MA
- $4.05
- Beta
- 1.38
- Avg Volume
- 129.77K
Get TickerSpark's AI analysis on TTNP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 25 | Ben-Tzvi Avraham | sell | 3,313 |
| Oct 1, 25 | Ben-Tzvi Avraham | sell | 5,000 |
| Mar 27, 25 | Loh Gabriel | other | 0 |
| Mar 20, 25 | Jye Chay Weei | other | 0 |
| Apr 2, 24 | Mokhtar Firdauz | other | 0 |
| Apr 2, 24 | Flores Francisco | other | 0 |
| Mar 18, 24 | Choong Choon Hau | other | 54,132 |
| Mar 18, 24 | Choong Choon Hau | other | 0 |
| Oct 25, 23 | NATAN DAVID | other | 16,250 |
| Oct 25, 23 | McMurdo Matthew Charles | other | 16,250 |
Our TTNP Coverage
We haven't published any research on TTNP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TTNP Report →Similar Companies
CMND+5.12%
Clearmind Medicine Inc.
$0.25
XBIO-2.24%
Xenetic Biosciences, Inc.
$2.83
SNGX+1.84%
Soligenix, Inc.
$0.38
ENSC+4.62%
Ensysce Biosciences, Inc.
$0.31
KZIA+7.37%
Kazia Therapeutics Limited
$12.97
CANF+6.46%
Can-Fite BioPharma Ltd.
$3.46
QLGN+5.59%
Qualigen Therapeutics, Inc.
$3.21
SILO-0.13%
Silo Pharma, Inc.
$0.37